129 related articles for article (PubMed ID: 38783246)
1. Prognostic value of 17-Gene genomic prostate score in patients with clinically localized prostate cancer: a meta-analysis.
Cui F; Tang X; Man C; Fan Y
BMC Cancer; 2024 May; 24(1):628. PubMed ID: 38783246
[TBL] [Abstract][Full Text] [Related]
2. A Biopsy-based 17-gene Genomic Prostate Score Predicts Recurrence After Radical Prostatectomy and Adverse Surgical Pathology in a Racially Diverse Population of Men with Clinically Low- and Intermediate-risk Prostate Cancer.
Cullen J; Rosner IL; Brand TC; Zhang N; Tsiatis AC; Moncur J; Ali A; Chen Y; Knezevic D; Maddala T; Lawrence HJ; Febbo PG; Srivastava S; Sesterhenn IA; McLeod DG
Eur Urol; 2015 Jul; 68(1):123-31. PubMed ID: 25465337
[TBL] [Abstract][Full Text] [Related]
3. A Biopsy-based 17-gene Genomic Prostate Score as a Predictor of Metastases and Prostate Cancer Death in Surgically Treated Men with Clinically Localized Disease.
Van Den Eeden SK; Lu R; Zhang N; Quesenberry CP; Shan J; Han JS; Tsiatis AC; Leimpeter AD; Lawrence HJ; Febbo PG; Presti JC
Eur Urol; 2018 Jan; 73(1):129-138. PubMed ID: 28988753
[TBL] [Abstract][Full Text] [Related]
4. The 17-Gene Genomic Prostate Score Test Is Prognostic for Outcomes After Primary External Beam Radiation Therapy in Men With Clinically Localized Prostate Cancer.
Janes JL; Boyer MJ; Bennett JP; Thomas VM; De Hoedt AM; Edwards V DK; Singla PK; Abran JM; Aboushwareb T; Salama JK; Freedland SJ
Int J Radiat Oncol Biol Phys; 2023 Jan; 115(1):120-131. PubMed ID: 36306979
[TBL] [Abstract][Full Text] [Related]
5. The 17-Gene Genomic Prostate Score Test as a Predictor of Outcomes in Men with Unfavorable Intermediate Risk Prostate Cancer.
Cullen J; Kuo HC; Shan J; Lu R; Aboushwareb T; Van Den Eeden SK
Urology; 2020 Sep; 143():103-111. PubMed ID: 32525077
[TBL] [Abstract][Full Text] [Related]
6. A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling.
Klein EA; Cooperberg MR; Magi-Galluzzi C; Simko JP; Falzarano SM; Maddala T; Chan JM; Li J; Cowan JE; Tsiatis AC; Cherbavaz DB; Pelham RJ; Tenggara-Hunter I; Baehner FL; Knezevic D; Febbo PG; Shak S; Kattan MW; Lee M; Carroll PR
Eur Urol; 2014 Sep; 66(3):550-60. PubMed ID: 24836057
[TBL] [Abstract][Full Text] [Related]
7. A 17-Gene Genomic Prostate Score as a Predictor of Adverse Pathology in Men on Active Surveillance.
Kornberg Z; Cooperberg MR; Cowan JE; Chan JM; Shinohara K; Simko JP; Tenggara I; Carroll PR
J Urol; 2019 Oct; 202(4):702-709. PubMed ID: 31026214
[TBL] [Abstract][Full Text] [Related]
8. The 17-gene Genomic Prostate Score assay as a predictor of biochemical recurrence in men with intermediate and high-risk prostate cancer.
Helfand BT; Paterakos M; Wang CH; Talaty P; Abran J; Bennett J; Hall DW; Lehman A; Aboushwareb T
PLoS One; 2022; 17(9):e0273782. PubMed ID: 36048818
[TBL] [Abstract][Full Text] [Related]
9. GPS Assay Association With Long-Term Cancer Outcomes: Twenty-Year Risk of Distant Metastasis and Prostate Cancer-Specific Mortality.
Brooks MA; Thomas L; Magi-Galluzzi C; Li J; Crager MR; Lu R; Abran J; Aboushwareb T; Klein EA
JCO Precis Oncol; 2021; 5():. PubMed ID: 34036236
[TBL] [Abstract][Full Text] [Related]
10. Validation of the Decipher Test for Predicting Distant Metastatic Recurrence in Men with High-risk Nonmetastatic Prostate Cancer 10 Years After Surgery.
Van den Broeck T; Moris L; Gevaert T; Tosco L; Smeets E; Fishbane N; Liu Y; Helsen C; Margrave J; Buerki C; Davicioni E; Van Poppel H; Everaerts W; Weinmann S; Den R; Davis J; Schaeffer E; Karnes RJ; Claessens F; Joniau S
Eur Urol Oncol; 2019 Sep; 2(5):589-596. PubMed ID: 31411980
[TBL] [Abstract][Full Text] [Related]
11. The 17-Gene Genomic Prostate Score Assay Predicts Outcome After Radical Prostatectomy Independent of PTEN Status.
Magi-Galluzzi C; Isharwal S; Falzarano SM; Tsiatis A; Dee A; Maddala T; Knezevic D; Febbo PG; Lawrence J; Klein EA
Urology; 2018 Nov; 121():132-138. PubMed ID: 30142405
[TBL] [Abstract][Full Text] [Related]
12. Ability of a Genomic Classifier to Predict Metastasis and Prostate Cancer-specific Mortality after Radiation or Surgery based on Needle Biopsy Specimens.
Nguyen PL; Haddad Z; Ross AE; Martin NE; Deheshi S; Lam LLC; Chelliserry J; Tosoian JJ; Lotan TL; Spratt DE; Stoyanova RS; Punnen S; Ong K; Buerki C; Aranes M; Kolisnik T; Margrave J; Yousefi K; Choeurng V; Davicioni E; Trock BJ; Kane CJ; Pollack A; Davis JW; Feng FY; Klein EA
Eur Urol; 2017 Nov; 72(5):845-852. PubMed ID: 28528811
[TBL] [Abstract][Full Text] [Related]
13. Validation of the prognostic value of a three-gene signature and clinical parameters-based risk score in prostate cancer patients.
Saemundsson A; Xu LD; Meisgen F; Cao R; Ahlgren G
Prostate; 2023 Sep; 83(12):1133-1140. PubMed ID: 36988135
[TBL] [Abstract][Full Text] [Related]
14. Comparing Prognostic Utility of a Single-marker Immunohistochemistry Approach with Commercial Gene Expression Profiling Following Radical Prostatectomy.
Leapman MS; Nguyen HG; Cowan JE; Xue L; Stohr B; Simko J; Cooperberg MR; Carroll PR
Eur Urol; 2018 Nov; 74(5):668-675. PubMed ID: 30181067
[TBL] [Abstract][Full Text] [Related]
15. Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study.
Lalonde E; Ishkanian AS; Sykes J; Fraser M; Ross-Adams H; Erho N; Dunning MJ; Halim S; Lamb AD; Moon NC; Zafarana G; Warren AY; Meng X; Thoms J; Grzadkowski MR; Berlin A; Have CL; Ramnarine VR; Yao CQ; Malloff CA; Lam LL; Xie H; Harding NJ; Mak DYF; Chu KC; Chong LC; Sendorek DH; P'ng C; Collins CC; Squire JA; Jurisica I; Cooper C; Eeles R; Pintilie M; Dal Pra A; Davicioni E; Lam WL; Milosevic M; Neal DE; van der Kwast T; Boutros PC; Bristow RG
Lancet Oncol; 2014 Dec; 15(13):1521-1532. PubMed ID: 25456371
[TBL] [Abstract][Full Text] [Related]
16. Validation of a Genomic Risk Classifier to Predict Prostate Cancer-specific Mortality in Men with Adverse Pathologic Features.
Karnes RJ; Choeurng V; Ross AE; Schaeffer EM; Klein EA; Freedland SJ; Erho N; Yousefi K; Takhar M; Davicioni E; Cooperberg MR; Trock BJ
Eur Urol; 2018 Feb; 73(2):168-175. PubMed ID: 28400167
[TBL] [Abstract][Full Text] [Related]
17. Advancing age within established Gleason score categories and the risk of prostate cancer-specific mortality (PCSM).
Russo AL; Chen MH; Aizer AA; Hattangadi JA; D'Amico AV
BJU Int; 2012 Oct; 110(7):973-9. PubMed ID: 22954029
[TBL] [Abstract][Full Text] [Related]
18. Local Failure Events in Prostate Cancer Treated with Radiotherapy: A Pooled Analysis of 18 Randomized Trials from the Meta-analysis of Randomized Trials in Cancer of the Prostate Consortium (LEVIATHAN).
Ma TM; Chu FI; Sandler H; Feng FY; Efstathiou JA; Jones CU; Roach M; Rosenthal SA; Pisansky T; Michalski JM; Bolla M; de Reijke TM; Maingon P; Neven A; Denham J; Steigler A; Joseph D; Nabid A; Souhami L; Carrier N; Incrocci L; Heemsbergen W; Pos FJ; Sydes MR; Dearnaley DP; Tree AC; Syndikus I; Hall E; Cruickshank C; Malone S; Roy S; Sun Y; Zaorsky NG; Nickols NG; Reiter RE; Rettig MB; Steinberg ML; Reddy VK; Xiang M; Romero T; Spratt DE; Kishan AU;
Eur Urol; 2022 Nov; 82(5):487-498. PubMed ID: 35934601
[TBL] [Abstract][Full Text] [Related]
19. Could aspirin be a lifesaver for prostate cancer patients in prostate cancer-specific mortality?: an update systematic review and meta-analysis.
Zhou J; Xia S; Li T; Liu R
BMC Cancer; 2019 Dec; 19(1):1186. PubMed ID: 31805980
[TBL] [Abstract][Full Text] [Related]
20. Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort.
Cooperberg MR; Davicioni E; Crisan A; Jenkins RB; Ghadessi M; Karnes RJ
Eur Urol; 2015 Feb; 67(2):326-33. PubMed ID: 24998118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
